Unknown

Dataset Information

0

Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes.


ABSTRACT: Background:Depression in patients with type 2 diabetes (T2D) is often undiagnosed and remains untreated, leading to poor therapy adherence and ill health-related outcomes. We evaluated the effect of vortioxetine versus sertraline in the treatment of depression, distress and metabolic control in subjects with T2D and depression. Methods:Participants were selected from the Clinic for Diabetes, diagnosed with depression when the score was ?14 in the Hamilton Depression Rating Scale, and verified by a psychiatrist in agreement with the DSM-5 instrument (Diagnostic and Statistical Manual of Mental Disorders, fifth edition). The criteria for recruitment also included glycosylated hemoglobin ?7.5%, 18 to 60 years of age, and written informed consent. Pharmacological treatment for depression was assigned randomly: vortioxetine (10 mg/day) or sertraline (75 mg/day) for 8 weeks. Biochemical parameters, anthropometric measures and depression symptoms were evaluated after antidepressant treatment. This was a randomized singled-blind study. Results:Subjects that met the inclusion criteria were 50, of which only 21 patients with T2D and depression finished the treatment. Vortioxetine and sertraline showed partial remission of depression. Vortioxetine showed a major effect size in glycosylated hemoglobin and a moderate effect size on weight loss, fasting plasma glucose (FPG), cholesterol and triacylglycerol levels. On the other hand, patients treated with sertraline presented a slight increase in body weight, body mass index (BMI), and in all biochemical markers. Conclusions:Vortioxetine may ameliorate depressive symptoms and metabolic control in patients with T2D and depression. Trial registration number: NCT03978286.

SUBMITTER: Tovilla-Zarate CA 

PROVIDER: S-EPMC6944547 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7288194 | biostudies-literature
| S-EPMC3356343 | biostudies-other
| S-EPMC6483322 | biostudies-literature
| S-EPMC3758402 | biostudies-literature
2016-07-15 | ST000421 | MetabolomicsWorkbench
| S-EPMC5959930 | biostudies-literature
| S-EPMC5836321 | biostudies-literature
| S-EPMC4785307 | biostudies-other
| S-EPMC8408521 | biostudies-literature
| S-EPMC7834928 | biostudies-literature